Compare SPIR & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SPIR | FHTX |
|---|---|---|
| Founded | 2012 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 533.0M | 332.2M |
| IPO Year | 2020 | 2020 |
| Metric | SPIR | FHTX |
|---|---|---|
| Price | $21.31 | $4.86 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 8 |
| Target Price | ★ $15.80 | $11.50 |
| AVG Volume (30 Days) | ★ 2.2M | 131.7K |
| Earning Date | 05-13-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 134.98 | 25.32 |
| EPS | ★ 1.49 | N/A |
| Revenue | ★ $110,451,000.00 | $30,909,000.00 |
| Revenue This Year | $11.91 | $7.81 |
| Revenue Next Year | $23.34 | $17.72 |
| P/E Ratio | $13.78 | ★ N/A |
| Revenue Growth | 13.15 | ★ 36.75 |
| 52 Week Low | $6.60 | $3.27 |
| 52 Week High | $23.59 | $6.95 |
| Indicator | SPIR | FHTX |
|---|---|---|
| Relative Strength Index (RSI) | 68.52 | 46.58 |
| Support Level | $8.16 | $4.42 |
| Resistance Level | N/A | $5.85 |
| Average True Range (ATR) | 2.19 | 0.27 |
| MACD | 0.60 | 0.03 |
| Stochastic Oscillator | 83.92 | 57.65 |
Spire Global Inc provides space-based data, analytics, and space services, offering datasets and insights about Earth to support decision-making. It builds, owns, and operates a constellation of nanosatellites that observe the Earth in real time using radio frequency (RF) technology. Additionally, it offers Space Services solutions that allow customers to deploy and scale their own satellite constellations using its platform, ground station network, manufacturing facilities, and launch partnerships. The company derives revenue from providing data, insights and access to its cloud-based technology platform sold on a subscription basis.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.